Shares of Getinge (OTCMKTS:GNGBY – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $22.69, but opened at $21.73. Getinge shares last traded at $21.73, with a volume of 1,074 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Nordea Equity Research raised Getinge from a “hold” rating to a “buy” rating in a research report on Wednesday, October 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Getinge has a consensus rating of “Moderate Buy”.
Check Out Our Latest Analysis on Getinge
Getinge Trading Up 2.3%
Getinge (OTCMKTS:GNGBY – Get Free Report) last posted its quarterly earnings results on Tuesday, October 21st. The company reported $0.25 earnings per share (EPS) for the quarter. Getinge had a net margin of 5.77% and a return on equity of 10.64%. The company had revenue of $864.74 million for the quarter.
About Getinge
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.
Recommended Stories
- Five stocks we like better than Getinge
- What is a Secondary Public Offering? What Investors Need to Know
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Investing in the High PE Growth Stocks
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- Why is the Ex-Dividend Date Significant to Investors?
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.
